Quantification of Elastase-Like Activity in 13 Human Cancer Cell Lines and in an Immortalized Human Epithelial Cell Line by RP-HPLC (original) (raw)
2003, Biological Chemistry
A sensitive and specific RP-HPLC assay was developed to measure the levels of polymorphonuclear elastase (PMN-E) activity in growing cell cultures. By combining a pre-incubation of the cells with a relatively non-toxic, PMN-E-specific inhibitor, MeOSuc-Ala-Ala-Pro-Val-chloromethylketone (MAAPVCK), the p-nitroaniline formed by the hydrolysis of the substrate MeOSuc-Ala-Ala-Pro-Val-p-NA by PMN-E is quantified. Elastase-like activity was measured in 14 human cells lines: 13 cancer cell lines (HL-60, U-937, A-427, LCLC-103H, YAPC, DAN-G, PA-TU-8902, KYSE-70,-510,-520, 5637, SISO and MCF-7) and one immortalized epithelial cell line (hTert-RPE1). Activity was detected in all lines; the lowest was found in hTert-RPE1 cells while the highest was detected in a pancreas adenocarcinoma line (PA-TU-8902). When the results were normalized according to cell volume instead of cell number, the leukemia line HL-60 had the highest activity and PA-TU-8902 ranked second. A 1 h pre-incubation with 9.0 µM of the irreversible PMN-E inhibitor MAAPVCK led to varying degrees of enzyme inhibition depending on the cell line; the strongest inhibition was observed with the PA-TU-8902 pancreatic cancer cell line (90% inhibition) while the weakest was seen with the A-427 lung cancer cell line (52%). These results indicate that PA-TU-8902 is a suitable in vitro model for testing the efficacy of PMN-E-activated prodrugs of antitumor agents.
Sign up for access to the world's latest research.
checkGet notified about relevant papers
checkSave papers to use in your research
checkJoin the discussion with peers
checkTrack your impact
Related papers
Journal of Cellular Biochemistry, 1995
Our studies utilizing different types of protease inhibitors as anticarcinogenic agents in in viva and in vitro systems have recently been reviewed. These studies suggest that the protease inhibitors which prevent carcinogenesis affect processes in the early stages of carcinogenesis, although they can be effective at long time periods after carcinogen exposure in both in vitro and in viva systems. While there is strong evidence that these protease inhibitors can affect both the initiation and promotion stages of carcinogenesis, they have no effect on already transformed cells. Our results have suggested that the first event in carcinogenesis is a high frequency epigenetic event and that a later event, presumably genetic, leads to the malignant state. Protease inhibitors appear capable of reversing the initiating event, presumably by stopping an ongoing cellular process begun by carcinogen exposure. The major lines of investigation on the mechanism of the protease inhibitor suppression of carcinogenesis relate to the ability of anticarcinogenic protease inhibitors to affect the expression of certain oncogenes, and the levels of certain types of proteolytic activities. The anticarcinogenic protease inhibitors have no observable effects on normal cells, but can reverse carcinogen-induced cellular changes for several different endpoints studied. The most direct method of determining the mechanism of action of the anticarcinogenic protease inhibitors is to identify and characterize the proteases with which they interact. In the cells of the in viva and in vitro systems in which protease inhibitors can prevent carcinogenesis, only a few proteases have been observed to interact with the anticarcinogenic protease inhibitors. Proteases have been identified by both substrate hydrolysis and affinity chromatography. Using substrate hydrolysis, we examined the ability of cell homogenates to cleave specific substrates and then determined the ability of various protease inhibitors to affect that hydrolyzing activity. Affinity chromatography can isolate specific proteases that directly interact with anticarcinogenic protease inhibitors. As examples, the Boc-Val-Pro-Arg-MCA hydrolyzing activity was identified by substrate hydrolysis, and a 43 kDa protease has been identified by affinity chromatography. The isolation and characterization of these proteases has been and will continue to be a subject of investigation in our laboratory. Our studies on anticarcinogenic protease inhibitors have suggested that the Bowman-Birk Inhibitor (BBI) derived from soybeans is a particularly effective anticarcinogenic protease inhibitor. BBI has been studied both as a pure protease inhibitor, or purified BBI (PBBI), and as an extract of soybeans enriched in BBI, termed BBI concentrate (BBIC). PBBI and/or BBIC have been shown to suppress carcinogenesis in three different species (mice, rats and hamsters); in several organ systems/tissue types (colon, liver, lung, esophagus and cheek pouch [oral epithelium]); in cells of both epithelial and connective tissue origin; when given to animals by several different routes of administration (including the diet); leading to different types of cancer (e.g., squamous cell carcinomas, adenocarcinomas, angiosarcomas, etc.
Canadian Journal of Physiology and Pharmacology, 2002
An elastase-2 has been recently described as the major angiotensin (Ang) II-forming enzyme of the rat mesenteric arterial bed (MAB) perfusate. Here, we have investigated the interaction of affinity-purified rat MAB elastase-2 with some substrates and inhibitors of both pancreatic elastases-2 and Ang II-forming chymases. The Ang II precursor [Pro11-D-Ala12]-Ang I was converted into Ang II by the rat MAB elastase-2 with a catalytic efficiency of 8.6 min1·µM1, and the chromogenic substrates N-succinyl-Ala-Ala-Pro-Leu-p-nitroanilide and N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide were hydrolyzed by the enzyme with catalytic efficiencies of 10.6 min1·µM1and 7.6 min1·µM1, respectively. The non-cleavable peptide inhibitor CH-5450 inhibited the rat MAB elastase-2 activities toward the substrates Ang I (IC50= 49 µM) and N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (IC50= 4.8 µM), whereas N-acetyl-Ala-Ala-Pro-Leu-chloromethylketone, an effective active site-directed inhibitor of pancreatic e...
Cancer Letters, 1990
Untransformed and malignantly-transformed mouse embryo fibroblasts were found to contain an enzymatic activity which hydrolysed the synthetic substrate, Suc-Ala-Ala-Pro-Phe-AMC. This activity, of approximate molecular weight 55,000, which has been partially purified by ion-exchange and gel-filtration chromatography, was maximally active at neutral pH, associated with subcellular organelles or membranes and inhibited by EDTA, EGTA, phosphoramidon and 1,lO phenanthroline, but not by PMSF or pepstatin, indicating that it may be a metalloprotease. Several other protease inhibitors, such as chymosfatin, TPCK
In Vitro Studies of Anticarcinogenic Protease Inhibitors
Protease Inhibitors as Cancer Chemopreventive Agents, 1993
Several different types of agents have been shown to modify the yield of transformed cells in vitro. We have observed that certain protease inhibitors have the ability to suppress radiation-and chemical-induced malignant transformation in vitro in a highly significant fashion (
Chapter V. Protease Inhibitors as Anticancer Agents
Protease inhibitors (PIs) encompass a large group of proteins that regulate the hydrolytic activity of proteolytic enzymes and play important physiological roles in all the living organisms. The protease/PI balance is necessary for cellular homeostasis, though, when such balance is broken, pathological conditions like cancer development are induced. The study of PIs as anti-cancer agents has been an important subject of research since more than three decades ago. There are a variety of mechanisms by which PIs perform their effects which depend on two main aspects: the nature, structure and functions of PI and, the interaction with a complex microenvironment that differs, even between cancers originated on the same source. There are many promissory cases, as well as, failures and paradoxical examples of PIs in the treatment of cancer which must be taken into consideration to propouse PI as possible part of the pharmaceutilcal strategies against cancer. In the following chapter the re...
FEBS Letters, 1989
Proteolytic enzymes released from granulocytes upon stimulation with the chemotactic N-formyl peptide FNLPNTL (in the presence of cytochalasin B) prevented activation of tumor cell single-chain urokinase-type plasminogen activator (pro-uPA) by plasmin. Elastase was identified by the use of eglin C (elastase inhibitor) and a monoclonai antibody to elastase as the functional proteolytic enzyme in granulocyte supernatants. Action of purified granulocyte elastase on pro-uPA generated enzymatically inactive two-chain uPA linked by disulfide bridges which was indistinguishable by SDS-PAGE from plasmin-generated HMW-uPA. The major elastase cleavage site in pro-uPA was located between Ile 159 and Ilca°°; a minor one between Thr 1~5 and Thr TM. Elastase cannot substitute for plasmin in the proteolytic activation of pro-uPA to enzymatically active HMW-uPA. However, when pro-uPA was first activated by plasmin to form enzymatically active HMW-uPA, this enzymatic activity was not impaired by sfibsequent elastase treatment. Prourokinase; Plasminogen activator; Elastase; Granulocyte; Chemotactic peptide; N-terminal amino acid sequence determination Published by Elsevier Science Publishers B. V. (Biomedical Division) 00145793/89/$3.50
Proceedings of the National Academy of Sciences, 1987
Several different protease inhibitors have the ability to suppress transformation in vitro and carcinogenesis in vivo. The mechanism(s) by which protease inhibitors suppress carcinogenesis, however, is not fully understood. Presumably, these agents inhibit one or more intracellular proteases whose functions are essential for the induction and/or expression of the transformed phenotype. We have isolated an endopeptidase activity capable of hydrolyzing the substrate Boc-Val-Pro-Arg-MCA (Boc = butoxycarbonyl; MCA = 7-amino-4-methylcoumarin) from C3H/10T½/ mouse embryo fibroblast cells. This
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.